Abstract
Introduction: There is a pressing need for COVID-19 transmission control and effective treatments. We aim to evaluate the safety and effectiveness of SARS-CoV-2 pharmacologic therapies as of August 2, 2020 according to study level of evidence.
Methods: PubMed, ScienceDirect, Cochrane Library, JAMA Network and PNAS were searched. The following keywords were used: ((COVID-19) OR (SARS-CoV-2)) AND ((((((therapeutics) OR (treatment)) OR (vaccine)) OR (hydroxychloroquine)) OR (antiviral)) OR (prognosis)). Results included peer-reviewed studies published in English.
Results: 15 peer-reviewed articles met study inclusion criteria, of which 14 were RCTs and one was a systematic review with meta-analysis. The following pharmacologic therapies were evaluated: chloroquine (CQ), hydroxychloroquine (HCQ), antivirals therapies, plasma therapy, anti-inflammatories, and a vaccine.
Conclusion: According to level 1 evidence reviewed here, the most effective SARS-Co-V-2 pharmacologic treatments include remdesivir for mild to severe disease, and a triple regimen therapy consisting of lopinavir-ritonavir, ribavirin and interferon beta-1b for mild to moderate disease. Also, dexamethasone significantly reduced mortality in those requiring respiratory support. However, there is still a great need for detailed level 1 evidence on pharmacologic therapies.
Keywords: COVID-19 clinical outcomes; COVID-19 pharmacologic treatments; Drug effectiveness; Drug safety; SARS-CoV-2.
【저자키워드】 SARS-CoV-2, COVID-19 clinical outcomes, COVID-19 pharmacologic treatments, Drug effectiveness, Drug safety, 【초록키워드】 COVID-19, Dexamethasone, Meta-analysis, SARS-CoV-2, Vaccine, therapy, Chloroquine, Mortality, Hydroxychloroquine, Antiviral, Prognosis, Lopinavir, Ritonavir, interferon, Remdesivir, systematic review, drug, ribavirin, RCT, plasma therapy, Effectiveness, Mild, plasma, network, HCQ, respiratory, Therapies, RCTs, Evidence, Lopinavir-ritonavir, severe disease, Respiratory Support, Interferon beta-1b, COVID-19 transmission, criteria, regimen, mild to moderate, level 1, interferon beta, pharmacologic treatment, mild to moderate disease, moderate disease, Cochrane Library, study inclusion, article, pharmacologic treatments, PNAS, effective, English, JAMA, Result, evaluate, significantly, include, reduced, searched, peer-reviewed, peer-reviewed study, 【제목키워드】 SARS-CoV-2, therapy, Evidence,